RA-ILD Prevalence and Serum Markers
The prevalence of ILD in rheumatoid arthritis ranges from 4-68% depending on detection method, with clinically significant disease occurring in approximately 10-14% of patients; the key serum markers are anti-CCP antibodies and elevated rheumatoid factor (RF) levels. 1
Prevalence of RA-ILD
The wide variability in reported prevalence reflects differences in assessment methodology:
- Population-based estimates: Clinically significant ILD occurs in approximately 10% of RA patients 2
- HRCT-based detection: Up to 33% of early RA patients (disease duration <2 years) show abnormalities consistent with ILD on HRCT, though only 14% are considered clinically significant 1
- Overall range: Published estimates span 4-68% depending on whether subclinical disease is included and the detection method used 1
- Lifetime risk: Population-based cohort studies demonstrate a lifetime risk of 7.7% for developing ILD in RA patients versus 0.9% in non-RA subjects, representing an 8.96-fold increased hazard 3
The discrepancy between radiologic findings and clinical significance is critical—approximately one-third of patients have subclinical disease with varying degrees of functional impairment 4.
Serum Markers for RA-ILD
The primary serum markers that predict RA-ILD development are:
Anti-CCP Antibodies
- Presence of anti-cyclic citrullinated peptide (CCP) antibodies is a major risk factor for ILD development 1, 5
- High-titer anti-CCP antibodies specifically increase risk 5
Rheumatoid Factor (RF)
- Elevated RF levels predict ILD development 1
- High-titer RF is associated with increased risk 5
- High titres of IgM rheumatoid factor specifically predict mortality in established RA-ILD 6
Elevated ESR
- Elevated erythrocyte sedimentation rate serves as an additional marker of ILD risk 1
Risk Stratification Model
A validated four-factor risk score (0-9 points) incorporates age, anti-CCP antibodies, RF, and smoking history, with a cut-off score of 5 yielding 86% sensitivity and 58% specificity for ILD presence 7.
Clinical Significance and Mortality Impact
The development of ILD dramatically worsens prognosis:
- 10-year mortality: 60.1% in RA-ILD versus 34.5% in RA without ILD 1
- Median survival after ILD diagnosis: Only 2.6-3.0 years 3, 2
- Mortality risk: 3-fold higher in RA patients with ILD compared to those without 3
- Contribution to excess mortality: ILD accounts for approximately 13% of the excess mortality in RA patients compared to the general population 3
Screening Recommendations
Given the devastating mortality impact, risk-based screening is essential:
- Baseline PFTs and HRCT should be performed in high-risk patients (male sex, older age at RA onset, smoking history, high-titer RF/anti-CCP, rheumatoid nodules, higher disease activity) 1, 5
- Yearly follow-up PFTs for high-risk populations 1
- Risk-based screening tools (such as the Juge score) should be utilized to identify patients requiring HRCT evaluation 1
The MUC5B variant represents an emerging genetic marker that may predict susceptibility to RA-ILD, though it is not yet part of routine clinical assessment 1.